Rob Rodrigues is a partner at RNA Law. Rob is a seasoned litigator specializing in high-stakes business and intellectual property disputes in Brazil. Renowned for his strategic acumen, Rob delivers unmatched expertise to FORTUNE 500 companies and dynamic startups alike. He expertly navigates complex legal landscapes, ensuring robust patent portfolio management for top-tier life sciences and telecommunications firms. His deep market insight positions him as a first-choice advisor for both acquisition and enforcement actions.
Rob’s excellence has been recognized by a number of leading publications. In 2024, Lexology listed him as a Legal Influencer in Dispute Resolution. Chambers describes Rob as a “superb litigator”, “a very competent professional”, and “outstanding in providing business-oriented advice.” Who’s Who Legal praises “his top-tier practice advising clients on life sciences-related patent litigation.” The Legal 500 reports that clients describe Rob as someone “who standards out for his strong background in both the IP area, both in terms of litigation and in relation to more technical topics.” Client testimonials in IAM Strategy 300 laud him for his “deep understanding of IP issues and keen strategic insight, which he leverages to add value and monetise portfolios.”
Throughout his career, Rob has spearheaded multiple preliminary injunction proceedings and trials for global companies in Brazil. He also facilitates monumental IP asset transactions, with a keen eye on managing risks.
A Stanford Law School LL.M. alumnus, Rob served as a lead editor of the Stanford Technology Law Review. He has contributed extensively to global technology law journals and currently holds an editorial role at the Kluwer IP Blog.
Over the past decade, Brazil has seen an increase in patent litigation, as the local economy grows and stabilizes. With more companies eyeing Brazil as a strategic country for the protection of IP, the patent system becomes more scrutinized and more complex patent cases are filed. On June 12, 2024, the Superior Court of Justice (Superior Tribunal de Justiça, or STJ), Brazil’s highest court with jurisdiction over non-constitutional matters, issued a ruling allowing invalidity defenses on an industrial design infringement lawsuit. Although the case involves industrial design, the court’s opinion contains non-precedential statements that are applicable to patent cases.
In May 2024, the Brazilian Senate Committee on Science, Technology, Innovation, and Informatics hosted two public hearings to discuss implementing Regulatory Data Protection (RDP) for pharmaceutical products of human use. The call for hearings (REQ 27/2023) was presented by Senator Izalci Lucas (Liberal Party). While recognizing that regulatory changes would have significant implications for the local industry, the healthcare system, and consumers, Sen. Lucas expressed concern that a lack of measures could discourage investment in R&D.
Did you know that Brazil’s medical device market is experiencing a surge, attracting billions in imports annually? This boom, however, is attracting not only legitimate businesses but also those looking to exploit loopholes. On average, more than US$6.7 billion worth of products are imported annually, with around 14,000 new products being introduced every year. One example is the increase in sales of equipment for endoscopic surgeries, given the rise in the number of bariatric surgeries, which already exceeds 70,000 procedures per year.
On February 20, 2024, a Brazilian congress member, Antônio Luiz Rodrigues Mano Júnior (known as Júnior Mano), introduced a bill to amend the national IP Statute (Law #9,279/96) and regulate the ownership of inventions generated by artificial intelligence systems. Bill #303/2024 proposes the addition of a paragraph to Article 6 of the IP Statute, which regulates ownership of inventions, with the following wording: “in the case of inventions autonomously generated by artificial intelligence system, the patent can be requested in the name of the artificial intelligence system that has created the invention, being the artificial intelligence system considered the inventor and owner of rights arising from the invention.”
Unlike other jurisdictions, injunctions in Brazil are no equitable remedy. There is no discretionary power of the court to decide whether to grant a permanent injunction upon the finding of infringement at the end of the proceedings. Injunctive relief is the primary remedy, and it can only be substituted by financial damages at the election of the plaintiff. Preliminary injunctions, on the other hand, are subjected to the discretion of the courts—and must pass a test of balance of hardships.